Triomics raises $22M Series B for oncology-specific AI
What's the deal? Triomics, a startup that uses AI to help oncologists and cancer centre staff automate data-heavy tasks like clinical trial matching and appointment prep, has raised $22M in Series B funding. Battery Ventures led the round, with Nexus Venture Partners, Lightspeed, Y Combinator, and others returning as backers.
Founded in 2021, Triomics builds AI models trained specifically on oncology data. It parses dense, multi-year medical records — sometimes thousands of pages per patient — and surfaces key information inside the tools clinicians already use.
Why now? Oncology breakthroughs are keeping patients alive longer, which is great news — but it also means medical records are growing far more complex. A typical chart includes physician notes, imaging and pathology reports, and even scanned faxes. That volume creates a serious administrative burden for already-stretched staff.
Triomics initially focused on matching patients to clinical trials but expanded as large language model capabilities grew. It now offers verifiable patient summaries that cut appointment prep time, and automates the submission of tumour reports to government registries — a legal mandate for cancer centres.
What could go wrong? Competition is fierce. AI medical scribes like Abridge and Microsoft's NuanceDealroom has a profile for this one. Try Dealroom → already summarise patient-doctor conversations, and generic AI agents are getting better at basic chart summaries. Triomics argues its edge lies in domain specificity — its models are purpose-built for oncology — but that moat could narrow as general-purpose tools improve.
The signal: Triomics' progression from a $15 million Series A in mid-2024 to this $22 million Series B — with a 10x jump in annualised recurring revenue — marks it as a Dealroom-classified "breakout" company at a time when investors are increasingly favouring vertical AI over horizontal plays. Battery Ventures leading the round, alongside returning backers Nexus Venture Partners, Lightspeed, and Y Combinator, suggests conviction that oncology-specific platforms can defend their niche even as general-purpose models improve.
Read more: TechCrunch
